title: A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study.
abstract: OBJECTIVE
  To determine the relationship between a strategy of enoxaparin (ENOX), early ST-segment resolution (STRes), and clinical outcomes on patients with ST-segment elevation myocardial infarction (STEMI) after fibrinolysis.
  
  
  RESULTS
  Baseline and 180 min ECGs were analysed in 3208 of the 20 479 patients in the ExTRACT-TIMI 25 trial, which randomifzed patients with STEMI to ENOX vs. unfractionated heparin (UFH) as adjunctive therapy. STRes was defined as complete (70%), partial (30-70%), or none (<30%). There was no evidence for a difference in STRes between the groups assigned to the ENOX or UFH (median 69.4 vs. 67.2%; P = 0.13). Among patients with complete STRes (n = 1100), ENOX significantly reduced death or non-fatal recurrent MI at 30 days when compared with UFH (4.4 vs. 9.9%; OR(adj) 0.39; P < 0.001), whereas there was no difference in patients with only partial or no STRes [14.2 vs. 12.5%; OR(adj) 1.0; P = 0.98 (n = 368) and 16.2 vs. 15.9%; OR(adj) 1.0; P = 0.97 (n = 830), P for interaction = 0.008].
  
  
  CONCLUSIONS
  When compared with UFH, a strategy of ENOX significantly reduces death or non-fatal recurrent MI in patients who achieved complete STRes, but not in patients with less STRes. These data suggest that a strategy of ENOX improves outcomes by preventing re-occlusion in patients achieving initial successful reperfusion after fibrinolytic therapy rather than by facilitating initial reperfusion.
authors.affiliation: TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA. bscirica@partners.org
authors.forename: Benjamin M
authors.initials: BM
authors.lastname: Scirica
authors.forename: David A
authors.initials: DA
authors.lastname: Morrow
authors.forename: Zygmunt
authors.initials: Z
authors.lastname: Sadowski
authors.forename: Mikhail
authors.initials: M
authors.lastname: Ruda
authors.forename: José Carlos
authors.initials: JC
authors.lastname: Nicolau
authors.forename: Robert P
authors.initials: RP
authors.lastname: Giugliano
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Wiviott
authors.forename: Marc S
authors.initials: MS
authors.lastname: Sabatine
authors.forename: Amy
authors.initials: A
authors.lastname: Shui
authors.forename: Elliott M
authors.initials: EM
authors.lastname: Antman
authors.forename: Eugene
authors.initials: E
authors.lastname: Braunwald
mesh_terms: D000368:Aged; D000991:Antithrombins / Q000627:therapeutic use*; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D055502:Secondary Prevention; D016019:Survival Analysis; D015912:Thrombolytic Therapy / Q000379:methods / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D000991:Antithrombins; D017984:Enoxaparin; D005343:Fibrinolytic Agents